Actavis announced that it has received final FDA approval for its Abbreviated New Drug Application (ANDA) of Clonidine Transdermal System, the generic version of Boehringer Ingelheim’s Catapres-TTS. Catapres-TTS is indicated for the treatment of hypertension.
Clonidine is a central alpha-agonist that stimulates alpha-adrenoreceptors in the brain stem. This action results in reducedsympathetic outflow from the central nervous system and in decreases in peripheral resistance, renal vascular resistance, heart rate, and blood pressure.
Catapres-TTS is available in 0.1mg/day, 0.2mg/day, and 0.3mg/day (for 7 days).
For more information call (800) 432-8534 or visit Actavis.com.